Stockreport

Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases

KB Financial Group Inc  (KB) 
US:NYSE Investor Relations: kbfg.com/eng/ir/main/ir_main.jsp
PDF Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-anti [Read more]